Alerts will be sent to your verified email
Verify Email
KIMIABL
|
Kimia Biosciences
|
Balaxi Pharma.
|
Vaidya Sane Ayur Lab
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Unclassified
|
|||
|
R&D as a % of Total Sales
|
4.79 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
-352.38 % | 29.33 % | 8.39 % |
|
5yr average Equity Multiplier
|
65.1 | 1.4 | 1.34 |
|
5yr Average Asset Turnover Ratio
|
1.17 | 1.5 | 1.57 |
|
5yr Avg Net Profit Margin
|
-2.03 % | 11.83 % | 3.83 % |
|
Price to Book
|
0.0 | 1.13 | 0.0 |
|
P/E
|
27.34 | 10.43 | 36.08 |
|
5yr Avg Cash Conversion Cycle
|
28.76 Days | 133.11 Days | -76.76 Days |
|
Inventory Days
|
94.07 Days | 87.41 Days | 11.33 Days |
|
Days Receivable
|
101.18 Days | 103.86 Days | 24.16 Days |
|
Days Payable
|
144.79 Days | 63.18 Days | 116.68 Days |
|
5yr Average Interest Coverage Ratio
|
0.28 | 57.05 | 6.88 |
|
5yr Avg ROCE
|
-0.98 % | 40.34 % | 12.91 % |
|
5yr Avg Operating Profit Margin
|
1.32 % | 18.05 % | 7.94 % |
|
5 yr average Debt to Equity
|
29.7 | 0.05 | 0.02 |
|
5yr CAGR Net Profit
|
n/a | -5.76 % | -10.61 % |
|
5yr Average Return on Assets
|
-2.12 % | 20.09 % | 6.19 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
74.94 % | 65.99 % | 66.34 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -6.87 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kimia Biosciences
|
Balaxi Pharma.
|
Vaidya Sane Ayur Lab
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|